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Primary Sarcoma of the Mediastinum
A Report of 16 Cases Referred to the British Columbia Cancer Agency
Matthew Paquette, BSc,* Pauline T. Truong, MDCM,*† Jason Hart, MD,*† Stuart O. Jones, BSc,*
Benjamin Martens, BA,*† Jennifer L. Christie, BSc,* Cheryl Alexander, CCHRA(C),*
and Howard Joe, MD*†
Background: Sarcoma arising in the mediastinum is a rare entity.
This study evaluates treatment and survival in a cohort of patients
with primary mediastinal sarcoma.
Methods: Between 1990 and 2006, 16 patients were referred to the
British Columbia Cancer Agency with histologically confirmed
sarcoma of mediastinal origin. Outcomes examined were disease-
free survival (DFS) and overall survival (OS).
Results: There were nine male and seven female patients. The
median age at diagnosis was 56 years (range 21–70 years). Thirteen
(81%) patients had localized disease, and three (19%) patients had
distant metastasis at diagnosis. Surgical resection was performed in
8 of 13 patients with localized disease. At a median follow-up of 18
months, 12 patients have died of disease, three were alive with
disease, and one was alive with no evidence of disease. In the entire
cohort, median DFS was 12 months (range 0–107 months), and
median OS was 18 months (range 1–193 months). Patients who
underwent surgery experienced improved DFS (p  0.054) and OS
(p  0.034). Eastern Cooperative Oncology Group performance
status 0 to 1 was associated with improved DFS (p 0.038) and OS
(p  0.007). The histologic subtype with the longest survival was
well-differentiated liposarcoma. Age, gender, tumor location, T and
N stage, tumor size, location, and grade were not associated with
significant survival differences.
Conclusion: Surgical resection was associated with more favorable
survival in patients with mediastinal sarcoma. However, the high
rates of progression and mortality underscore the need for more
effective adjuvant treatments.
Key Words: Sarcoma, Mediastinum, Surgery, Radiotherapy, Che-
motherapy, Survival.
(J Thorac Oncol. 2010;5: 898–906)
Soft tissue sarcomas are a heterogeneous group of malig-nant mesenchymal tumors that can affect various ana-
tomic locations, most commonly the extremities.1 Primary
sarcoma arising in the mediastinum is a rare entity, compris-
ing less than 10% of all adult primary mediastinal tumors and
less than 2% of all soft tissue sarcoma cases.2–4 There are few
data defining optimal therapy for this rare disease. Current
knowledge on treatment and outcomes in patients with me-
diastinal sarcoma is primarily based on institutional series,4–8
case studies,9–15 and data from sarcoma involving other
anatomic sites.16–24 Surgical resection has been reported to
confer survival benefit,4 but late presentation and delayed
diagnosis due to nonspecific symptoms can result in locally
advanced or metastatic disease at presentation. The role of
radiation therapy (RT) and systemic therapy and their impact
on prognosis have remained unclear.
This study is a population-based analysis of the clini-
copathologic characteristics, local and systemic treatment,
and survival in adult patients referred to a Canadian provin-
cial cancer care institution with primary sarcoma arising in
the mediastinum.
METHODS
Study Setting
The British Columbia Cancer Agency (BCCA) is a
tertiary care institution providing a province-wide, popula-
tion-based cancer control program for the residents of British
Columbia, Canada. All patients referred to the BCCA Sar-
coma Tumor Group are discussed in a multidisciplinary
forum by a specialized team of surgeons, radiation and
medical oncologists, pathologists, and radiologists convening
weekly to review all pertinent records, investigations, and
pathology of each case. Individualized management recom-
mendations are made by the multidisciplinary team and
communicated to the referring physicians and treating on-
cologists. The chemotherapy regimens used were consistent
with systemic therapy regimens endorsed provincially by the
BCCA Sarcoma Tumor Group.
Study Subjects
Between January 1, 1990, and December 31, 2006,
2767 patients were referred to the BCCA with newly diag-
nosed primary sarcoma. Of these, 19 (0.7%) cases were
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mediastinal in origin. Three cases were excluded, one with
age 18 years, one with lacking pathologic and treatment
information, and one with a final diagnosis of sclerosing
mediastinitis rather than malignant sarcoma. The remaining
16 patients formed the study cohort of this analysis.
Data Abstraction and Analysis
Retrospective chart review was performed to abstract
data on patient, tumor, and treatment characteristics, response
to treatment, and survival outcomes. Response to therapy was
classified as complete response, partial response, or no re-
sponse based on the World Health Organization Handbook
for Reporting Results of Cancer.25 Complete response was
defined as the disappearance of all known disease. For pa-
tients treated with surgery, we also defined complete response
as the resection of all gross disease. Partial response was
defined as 50% or more decrease in total tumor size, with no
new lesions or progression of any lesion. No response was
defined as no change or when a 50% decrease in total tumor
size could not be established.25
Performance status was graded using the Eastern Co-
operative Oncology Group criteria.26
Disease-free survival (DFS) and overall survival (OS)
were computed using Kaplan-Meier methods. The log-rank
test was used to compare survival between different sub-
groups. Statistical tests were two sided, with significance
established at p  0.05. All analyses were conducted using
Statistical Package for Social Sciences software, version
14.0.2 (SPSS, Chicago, IL).
The study was approved by the University of British
Columbia research ethics board.
RESULTS
Patient and Tumor Characteristics
Clinicopathologic characteristics of the study cohort are
summarized in Table 1. There were nine male and seven
female patients. The median age at diagnosis was 56 years
(range 21–70 years). Thirteen (81%) patients had localized
disease, and three (19%) patients had distant metastasis at
diagnosis.
Treatment Characteristics
Local and systemic treatment, response to treatment,
time to progression, and survival are summarized in Table 2.
Surgical resection was performed in 8 of 13 patients with
localized disease. Of these, one had wide local excision with
negative surgical margins, six had positive margins, and one
had unknown margin status. The characteristics of patients
treated with versus without surgery are presented in Table 3.
There were higher proportions of patients with poor perfor-
mance status and metastatic disease in the no surgery group.
In the five patients with localized disease who did not
undergo surgery, the disease was deemed to be unresectable
because of disease extent or intimacy with the major vessels
and heart structures. Four of these five patients had poor
performances status, Eastern Cooperative Oncology Group
score 2. In the six patients with positive margins, the
median tumor size was 11.5 cm (range 6.5–16 cm).
RT as part of initial treatment was used with radical
intent in 7 of 13 patients with localized disease and with
palliative intent in two of three patients with metastatic
disease at diagnosis. Among seven patients with localized
disease who underwent RT, five patients had postoperative
RT and one patient had RT alone, all targeting the mediasti-
num, with total doses ranging from 40 to 60 Gray, in 20 to 30
fractions.
Chemotherapy, alone or in combination with local
therapy, was used in 4 of 13 patients with localized disease
and 1 of 3 patients with metastatic disease. Chemotherapy
alone was used in two patients with unresectable localized
disease. One patient with synovial sarcoma received doxoru-
bicin and ifosfamide but discontinued treatment after one
cycle because of local progression. One patient with undif-
ferentiated pleomorphic sarcoma received single-agent doxo-
rubicin, with no response, and died of disease after one cycle.
Preoperative chemotherapy, using ifosfamide-mesna and eto-
poside, alternating with vincristine, doxorubicin, and cyclo-
phosphamide, total eight cycles, was used in one patient with
embryonal rhabdomyosarcoma, resulting in partial response.
One patient with a Ewing family tumor received ifosfamide-
mesna and etoposide alternating with vincristine, doxorubi-
cin, and cyclophosphamide, total six cycles, with no re-
sponse. This patient subsequently underwent total body
irradiation and autologous stem cell transplant, followed by
mediastinal RT, also with no response.
Relapse and Survival Outcomes
Relapse and survival in each subject are summarized in
Table 2. At a median follow-up of 18 months, 9 of 13 patients
with localized disease have experienced disease progression:
two local, six distant, and one both local and distant progres-
sion (Table 2). The median time to progression was 9 months
(range 0–38 months).
Overall, 12 patients have died of disease, three were
alive with disease, and one was alive with no evidence of
disease. In the entire cohort, mean and median DFS were 21
months and 12 months, respectively (range 0–107 months),
and mean and median OS were 34 months and 18 months,
respectively (range 1–193 months) (Figures 1A and B).
Performance status was associated with DFS (p 
0.038) and OS (p  0.007) (Table 1). The histologic subtype
associated with the most favorable survival was well-differ-
entiated liposarcoma (Table 2). Age, gender, tumor location,
T and N stage, tumor size, location, and grade were not
associated with significant survival differences.
Survival According to Treatment
Characteristics
In patients with localized disease, surgical treatment
was associated with improved OS (p 0.034) and a trend for
improved DFS (p  0.054) (Figures 2A and B). The median
OS was 27 months (range 6–193 months) in eight patients
treated with surgery, when compared with 5 months (range
1–38 months) in five patients who did not undergo surgery
(Figure 2B).
OS was not significantly different in patients treated
with surgery alone compared with surgery and postoperative
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RT (p  0.107) and in patients with localized disease treated
with versus without RT (p  0.852).
Among patients with localized disease at diagnosis,
median OS durations were 8 months (range 1–16 months) in
four patients treated with chemotherapy and 28 months
(range 4–193 months) in nine patients treated without che-
motherapy (p  0.010).
Response to therapy was significantly associated with
DFS (p  0.001) and OS (p  0.007) (Figures 3A and B).
Mean OS durations were 95 months (range 26–193 months)
TABLE 1. Clinical Characteristics and Associated Disease-Free Survival and Overall Survival
Variables n (%)
Disease-Free Survival Median,
Range (mo) Pa
Overall Survival Median,
Range (mo) Pa
All 16 (100) 11.5 (0–107) — 18 (1–193) —
Gender 0.704 0.908
Male 9 (60) 9 (0–107) 11 (1–193)
Female 7 (40) 14 (0–35) 26 (4–38)
Age (yr) 0.658 0.945
50 7 (40) 9 (0–40) 16 (1–193)
50 9 (60) 17 (0–107) 26 (1–107)
Eastern Cooperative Oncology Group
performance Status
0.038 0.007
0–1 3 (19) 40 (14–67) 67 (28–193)
2 8 (50) 3 (0–17) 4.5 (1–26)
Unknown 5 (31) 24 (0–107) 26 (6–107)
Histologic subtype 0.009 0.002
Liposarcoma, well differentiated 2 (13) 87 (67–107) 87 (67–107)
Liposarcoma, not otherwise specified 1 (6) 24 26
Synovial sarcoma 3 (19) 35 (2–40) . 38 (5–193)
Unspecified sarcoma/Spindle cell sarcoma 3 (19) 2 (0–14) 6 (2–28)
Leiomyosarcoma 2 (13) 8.5 (0–17) 23 (20–26)
Embryonal rhabdomyosarcoma 1 (6) 15 16
Ewing family tumor 1 (6) 9 11
Angiosarcoma 1 (6) 4 4
Undifferentiated pleomorphic sarcoma 2 (13) 1 (0–1) 1 (1–1)
T stage 0.789 0.417
T1B 1 (6) 0 20
T2B 14 (88) 14.5 (0–107) 21 (1–193)
TX 1 (6) 0 1.0
N stage 0.515 0.515
N0 3 (19) 35 (2–40) 38 (6–193)
N1 1 (6) 9 11
NX 12 (75) 9 (0–107) 18 (1–107)
M stage 0.002 0.262
M0/MX 13 (81) 15 (1–107) 26 (1–193)
M1 3 (19) 0 2 (1–20)
Tumor size (cm) 0.348 0.512
10 5 (31) 9 (0–35) 20 (2–38)
10–15 5 (31) 24 (4–107) 26 (4–193)
15 5 (31) 2 (1–67) 6 (1–67)
Unknown 1 (6) 0 1
Tumor location 0.519 0.309
Anterior 4 (25) 14.5 (1–40) 22 (1–193)
Posterior 3 (19) 2 (0–17) 5 (2–26)
Not specified 9 (56) 9 (0–107) 20 (1–107)
Grade 0.888 0.952
I and II 4 (25) 1.5 (0–107) 13 (1–107)
III and IV 8 (50) 20.5 (0–67) 26 (2–193)
Unknown 4 (25) 6.5 (0–14) 7.5 (1–28)
a Log-rank statistics performed on known values only.
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in three patients with complete response, 43 months (range
16–107 months) in five patients with partial response, and 8
months (range 1–20 months) in six patients with no response
(Figure 3B).
DISCUSSION
Primary sarcomas arising in the mediastinum are rare.
At the BCCA, they account for less than 1% of all referred
sarcoma cases, a finding comparable with other reports.4
Available data on treatment and outcomes specific to patients
with mediastinal sarcoma are limited to institutional se-
ries,4–8 anecdotal case reports,9–13 and collective reviews of
case reports.14,15
Table 4 summarizes published series reporting treat-
ment and outcomes in patients with primary mediastinal
sarcoma to place in context with the current report. Relative
to other studies, this study is among the more contemporary
series available. Distinct from other populations, the patients
in this analysis were derived from a geographically defined
population with universal health care access, including onco-
logic treatment services coordinated by a centralized provin-
cial program funding all chemotherapeutic drugs and RT
delivery. Although there were no standard treatment proto-
cols specific to mediastinal sarcoma because of its rarity,
general consensus guidelines in soft tissue sarcoma manage-
ment were available.27 In addition, all patients were reviewed
in a multidisciplinary forum by the BCCA Sarcoma Tumor
Group, a team of specialists with expertise in the diagnosis,
pathologic examination, and treatment of soft tissue sarcoma.
Our study has documented a range of individualized
treatment strategies for patients with mediastinal sarcoma and
corroborated others’ findings of heterogeneity in disease
response and survival outcomes.4–8 The mean OS of 34
months in the present series is comparable with other series
reporting mean survival ranges of 4 to 30 months.4–8 Al-
though the study has identified several clinical factors asso-
ciated with more favorable survival, the high rates of pro-
gression and limited survival emphasize the need for more
effective treatments.
The impact of patient demographics and clinicopatho-
logic characteristics on survival in patients with mediastinal
sarcoma is unclear. The median age of 56 years in our cohort
is comparable with other series reporting median ages of 35
to 58 years.4–8 Although the male to female ratio in our
cohort was 1.3, others have found a higher male predomi-
nance with male to female ratios of 1.6 to 2.0.4,7 Age and
gender were not associated with significant survival differ-
ences in the current analysis. The finding that performance
status was significantly correlated with survival corroborates
other studies16,17 and suggests that this factor can be used in
clinical decisions and prognosis estimates.
Distinct from some series limited to one histologic
subtype,5,7,8 this study evaluated all histologic subtypes to
assess whether there may be survival variations associated
with different subtypes. Survival was most favorable in
patients with well-differentiated liposarcoma and least favor-
able in patients with undifferentiated pleomorphic sarcoma
and angiosarcoma. These findings, however, should be inter-
preted with caution because of small patient samples with this
rare disease. Acknowledging the caveat with small samples,
the relatively longer survival seen in association with well-
differentiated liposarcoma is consistent with some case re-
ports12,15 and institutional series.8 Similarly, the rapid rates of
tumor progression and poor survival observed with undiffer-
entiated pleomorphic sarcoma and angiosarcoma have also
been described by others, suggesting that these subtypes have
a more aggressive biology.13,17,18
The guiding principle in the surgical management of
soft tissue sarcoma is to achieve complete removal of the
TABLE 3. Clinical Characteristics, Overall Survival, and
Disease-Free Survival of Patients Treated with Versus without
Surgery
Variable
Surgery
(n  8)
n (%)
No Surgery
(n  8)
n (%) pa
OS (mo) 0.034
Median (range) 27 (6–193) 4.5 (1–38)
DFS (mo) 0.054
Median (range) 20.5 (2–107) 1.5 (0–35)
Gender 0.614
Male 4 (50) 5 (62.5)
Female 4 (50) 3 (37.5)
Age (yr)
50 3 (37.5) 4 (50)
50 5 (62.5) 4 (50)
Eastern Cooperative
Oncology Group
Performance Status
0.026
0–1 3 (37.5) 0
2 2 (25) 6 (75)
Unknown 3 (37.5) 2 (25)
T stage 0.268
T1B 0 1 (12.5)
T2B 8 (100) 6 (75)
TX 0 1 (12.5)
N stage 0.513
N0 2 (25) 1 (12.5)
N1 0 1 (12.5)
NX 6 (75) 6 (75)
M stage 0.055
M0/MX 8 (100) 5 (62.5)
M1 0 3 (37.5)
Tumor size (cm) 0.153
Median (range) 8 (2–24) 13 (6.5–20)
10 1 (12.5) 4 (50)
10–15 4 (50) 1 (12.5)
15 3 (37.5) 2 (25)
Unknown 0 1 (12.5)
Grade 0.679
I and II 2 (25) 2 (25)
III and IV 5 (62.5) 3 (37.5)
Unknown 1 (12.5) 3 (37.5)
a Statistics performed on known values only.
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primary tumor, preserve function, and minimize the risk of
local recurrence.19,27 In this series, patients with localized
disease treated with surgery experienced significantly im-
proved survival relative to patients treated without surgery.
Although the demonstration of survival benefits with surgical
resection is clear, the ability to perform wide local excision
with negative resection margins in patients with mediastinal
sarcoma can be challenging, particularly with extensive,
bulky disease invading major vessels and adjacent cardiopul-
monary structures.
The difficulty in achieving complete tumor clearance is
reflected by the high rates of positive margins in our series,
with only one patient having negative margins after surgery.
In our series, the reasons for positive margins were predom-
inantly large tumors with invasion into blood vessels and
adjacent critical structures. Similarly, in a series of 24 pa-
tients with mediastinal liposarcoma reported by Hahn and
Fletcher,8 among 14 patients who underwent surgery, nine
had positive margins, three had close margins, and two had
unknown margin status. In a study of 395 patients with soft
tissue sarcoma of various primary sites, Stefanovski et al.16
identified positive margin to be a strong prognostic predictor
for both local relapse and mortality. Burt et al.4 reported
similar findings in an analysis of the Memorial Sloan Ketter-
FIGURE 1. A, Disease-free survival
and B, overall survival of the entire
cohort.
FIGURE 2. A, Disease-free survival
and B, overall survival according to
surgery for localized disease.
FIGURE 3. A, Disease-free survival
and B, overall survival according to
response to therapy.
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ing Cancer Center’s experience treating 47 patients with
mediastinal sarcoma more than five decades from 1940 to
1991. The most significant factor associated with survival
was complete surgical resection. In that series, the 5-year
survival with complete resection was 49%, when compared
with 18% with incomplete or no resection.4 These outcomes
underscore the importance of early diagnosis to improve the
feasibility to perform complete resection and the need for
new treatment strategies to address the problem of residual
disease or positive margins after surgery.
Evidence-based recommendations guiding RT deci-
sions for soft tissue sarcoma have been primarily based on
prospective trials of patients with sarcoma involving the
extremities.19–22 These trials have demonstrated that com-
bined surgery and RT confer improved local control, but not
survival, in patients with nonmetastatic disease.19–21 Our
analysis did not find survival differences in patients who
underwent surgery plus postoperative RT compared with
patients treated with surgery alone. Interestingly, the two
patients treated with surgery alone had well-differentiated
liposarcoma, and both have remained alive without local or
distant progression. In contrast, among the five patients who
underwent surgery plus postoperative RT, all of whom had
positive margins, five had local disease control but developed
distant metastasis within 12 to 38 months, and one patient
developed rapid progression both locally and distantly. These
outcomes are likely related to patients with higher risk dis-
ease being selected for postoperative RT whereas patients
with lower risk disease were managed with surgery alone.
We acknowledge that our retrospective study is limited
by small samples and inherent biases in patient and treatment
selection and that there are few data reporting outcomes after
RT in patients with mediastinal sarcoma with which to
compare our results. Despite these caveats, the observation in
this series that the majority (4 of 5) of patients who received
postoperative RT were locally controlled and the concern that
thoracic disease progression can lead to symptom distress and
reduced quality of life support the consideration of using
mediastinal RT to optimize local control, particularly in cases
of unresectable tumors or residual disease after surgery.
The role of chemotherapy in mediastinal sarcoma man-
agement has not been established because of limited data.
The BCCA Sarcoma Tumor Group’s treatment policy ac-
knowledged that routine postoperative chemotherapy for soft
tissue sarcoma is controversial.27 In other studies reporting
chemotherapy use in patients with mediastinal sarcoma, most
have used doxorubicin-based regimens, in various combi-
nations with agents including cyclophosphamide, ifosf-
amide, etoposide, and cis-platin.4,8,14,15 These studies, sim-
ilar to ours, found varied tumor response and survival
outcomes.4,8,14,15 The small numbers of patients treated
with chemotherapy in this and other studies preclude the
ability to draw conclusions regarding what constitutes opti-
mal systemic therapy and whether neoadjuvant or adjuvant
approaches should be used.
At the BCCA, general guidelines are available for
specific settings where chemotherapy is an integral compo-
nent of multimodality therapy for sarcoma.27 These includeTA
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rhabdomyosarcoma, Ewing sarcoma, and other small round
blue cell tumors.27 Accordingly, alternating ifosfamide-
mesna/etoposide and vincristine/doxorubicin/cyclophos-
phamide were used as preoperative therapy in one case of
embryonal rhabdomyosarcoma and as primary therapy in
conjunction with RT and bone marrow transplant in one
case of Ewing family tumor. In both cases, survival was
poor with distant dissemination occurring within 6 months
after therapy.
Although our series is among the largest available
series, it remains small in absolute numbers because of the
rarity of this disease. Given the small numbers and hetero-
geneity in clinical and treatment characteristics, it is not
possible to perform multivariate analyses to control for con-
founders and that interpretation of small subgroup compari-
sons must be done with caution. These limitations prohibit
the ability to formulate guidelines as the management of
patients with this rare disease must be individualized depend-
ing on the extent of disease at diagnosis and the patient’s
physiologic reserve. Thus, we advocate the policy of thor-
ough review of each case, including imaging and pathologic
review, in an interdisciplinary forum to obtain consensus
regarding optimal treatment, with the understanding that the
final treatment recommendations for each patient can only be
made after careful, individualized assessment by the surgeon
and oncologist.
Research efforts are warranted to examine new local
and systemic treatments that may be used in conjunction with
surgery to improve disease control and survival in patients
with mediastinal sarcoma. Innovative RT techniques includ-
ing intensity-modulated RT and conformal treatment plan-
ning incorporating functional imaging data have the potential
to improve intrathoracic tumor targeting and reduce normal
tissue exposure.28,29 Intraoperative brachytherapy using per-
manent Iodine-125 interstitial planar seed implants applied to
high-risk intrathoracic regions at the time of surgery is a new
strategy that may be particularly useful for patients with
close or positive margins.30 Molecular analysis of sarcoma
pathology and identification of targets for molecular ther-
apy have also advanced in recent years.31 The evaluation
of these prognostic and therapeutic innovations to advance
care for patients with mediastinal sarcoma will succeed
only with continued multidisciplinary clinical and research
collaboration.
CONCLUSION
In patients with mediastinal sarcoma, good perfor-
mance status, well-differentiated liposarcoma, surgical resec-
tion, and complete response to therapy were associated with
more favorable survival. The majority of patients treated with
surgery and postoperative RT had local disease control but
progressed distantly. The high rates of disease progression
and mortality emphasize the need for more effective local and
systemic treatments. Given the rarity and complexity of
mediastinal sarcomas, a policy of reviewing each case in an
interdisciplinary forum is advocated to optimize individual-
ized treatment decisions for these patients.
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